The federal government has negotiated a series of agreements with major pharmaceutical companies to offer certain drugs at dramatically reduced prices to U.S. consumers.
The agreements resulted from President Donald Trump’s Most Favored Nation prescription price policy, initiated in May, which asked drugmakers to offer their lowest prices in the United States voluntarily.
